Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Lymphoma, Extranodal NK-T-Cell
Interventions
DRUG

Pembrolizumab

50 mg powder for concentrate for solution for infusion

RADIATION

Involved Field Radiation Therapy

"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."

Trial Locations (2)

200025

RECRUITING

Shanghai Rui-Jin Hospital, Shanghai

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER